Skip to main content
Clinical Trials/JPRN-UMIN000030857
JPRN-UMIN000030857
Completed
未知

Exploratory study on effectiveness and safety of long-term administration of Rikkunshito for improvement of anorexia and quality of life in patients with Parkinson's disease accompanied by apathy. - Exploratory study on effectiveness and safety of long-term administration of Rikkunshito for improvement of anorexia and quality of life in patients with Parkinson's disease accompanied by apathy.

Saitama Medical Center, Saitama Medical University0 sites30 target enrollmentJanuary 17, 2018

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Saitama Medical Center, Saitama Medical University
Enrollment
30
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 17, 2018
End Date
March 31, 2019
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Saitama Medical Center, Saitama Medical University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patients applicable to any one of the following items are excluded. (1\) Patients complicated of dementia (patients with MoCA\-J of 25 or less) (2\) Patients with depression, psychiatric symptoms (3\) Patients with abnormalities judged to require treatment by brain MRI (performed within 6 months) (4\) Patients who can not orally administer (5\) Patients who took herbal medicine within the first month before the start of the study (6\) Patients who can not discontinue combination use prohibited medicine during the observation period from two weeks before the start of the study (7\) Patients complicated of serious complications (heart, liver, kidney function disorder, hematopoietic disorder, malignant tumor etc.) or other diseases judged to affect life (8\) Patients allergic to traditional Chinese medicine (9\) Patients judged unsuitable by research researcher or research sharing doctor However, MoCA\-J of (1\) is carried out twice at intervals of 4 weeks, and patients who were 25 points or less at once are excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials